You have 9 free searches left this month | for more free features.

inc280

Showing 1 - 19 of 19

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Advanced Hepatocellular Carcinoma With c-MET Dysregulation Trial in Worldwide (INC280)

Active, not recruiting
  • Advanced Hepatocellular Carcinoma With c-MET Dysregulation
  • INC280
  • Nanjing, Jiangsu, China
  • +7 more
Jan 12, 2023

Kidney Cancer Trial run by the NCI (INC280)

Completed
  • Kidney Cancer
  • INC280
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 18, 2021

Recurrent NSCLC Trial in Sacramento, San Francisco (INC280, erlotinib HCl)

Completed
  • Recurrent Non-small Cell Lung Cancer
  • INC280
  • erlotinib hydrochloride
  • Sacramento, California
  • +1 more
Oct 11, 2021

Non Small Cell Lung Cancer Trial in Worldwide (EGF816, INC280, Nivolumab)

Terminated
  • Non Small Cell Lung Cancer
  • Houston, Texas
  • +12 more
Jan 31, 2022

Advanced Hepatocellular Carcinoma Trial in Worldwide (PDR001, INC280)

Completed
  • Advanced Hepatocellular Carcinoma
  • Toronto, Ontario, Canada
  • +16 more
Jul 29, 2021

EGFR-mutant NSCLC Trial in Worldwide (EGF816, trametinib, ribociclib)

Active, not recruiting
  • EGFR-mutant Non-small Cell Lung Cancer
  • Toronto, Ontario, Canada
  • +10 more
Dec 5, 2022

Advanced Solid Tumor Trial in Kashiwa, Fukuoka (INC280)

Completed
  • Advanced Solid Tumor
  • INC280
  • Kashiwa, Chiba, Japan
  • +1 more
Dec 16, 2020

Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma Trial in Guangzhou (BYL719, INC280, LDK378)

Completed
  • Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma
  • Guangzhou, Guangdong, China
    Novartis Investigative Site
Nov 20, 2020

Hepatic Impairment Trial in United States (INC280)

Completed
  • Hepatic Impairment
  • INC280
  • Miami, Florida
  • +4 more
Dec 8, 2020

cMET Dysegulation Advanced Solid Tumors Trial in Worldwide (INC280)

Completed
  • cMET Dysegulation Advanced Solid Tumors
  • INC280
  • Indianapolis, Indiana
  • +16 more
Dec 16, 2020

cMET-dysregulated Advanced Solid Tumors Trial in Worldwide (INC280, Midazolam, Caffeine)

Completed
  • cMET-dysregulated Advanced Solid Tumors
  • INC280
  • +2 more
  • Atlanta, Georgia
  • +11 more
Dec 8, 2020

cMET-dysregulated Advanced Solid Tumors Trial in Worldwide (INC280, digoxin, rosuvastatin)

Completed
  • cMET-dysregulated Advanced Solid Tumors
  • INC280
  • +2 more
  • Atlanta, Georgia
  • +14 more
Dec 8, 2020

NSCLC Trial in Worldwide (INC280, Gefitinib)

Completed
  • Non-small Cell Lung Cancer
  • Woolloongabba, Queensland, Australia
  • +30 more
Mar 12, 2021

Solid Tumors Trial in Worldwide (INC280)

Completed
  • Solid Tumors
  • INC280
  • Fayetteville, Arkansas
  • +46 more
Dec 16, 2020

Melanoma Trial in Worldwide (LGX818, MEK162, LEE011)

Active, not recruiting
  • Melanoma
  • Los Angeles, California
  • +31 more
Jun 11, 2021

Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Colorectal Cancer Trial in Worldwide (INC280, cetuximab)

Terminated
  • Squamous Cell Carcinoma of Head and Neck (SCCHN)
  • Metastatic Colorectal Cancer
  • Boston, Massachusetts
  • +14 more
Jan 17, 2019

Carcinoma, Non-Small-Cell Lung Cancer Trial (INC280)

Withdrawn
  • Carcinoma
  • Non-Small-Cell Lung Cancer
  • INC280
  • (no location specified)
Jul 24, 2018

c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280,

Terminated
  • c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM
  • Boston, Massachusetts
  • +12 more
May 29, 2018

Advanced Hepatocellular Carcinoma Trial in Worldwide (INC280, Placebo)

Withdrawn
  • Advanced Hepatocellular Carcinoma
  • INC280
  • Placebo
  • Boston, Massachusetts
  • +14 more
Aug 30, 2016